Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

Canadian Cancer Trials Group MEC.3 / ECOG E1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma - has met its accrual goal and was closed to accrual August 15, 2014.

Canadian centres contributed 44 / 1649 patients to this intergroup trial. It is expected that all Canadian patients will have completed protocol therapy by November 2015.

Thanks to all participating centres, staff and patients for contributing to this trial.